155 related articles for article (PubMed ID: 33546988)
1. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
Gupta GK; Perreault S; Seropian SE; Tormey CA; Hendrickson JE
Transfus Apher Sci; 2021 Jun; 60(3):103069. PubMed ID: 33546988
[TBL] [Abstract][Full Text] [Related]
2. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T; Sullivan HC; Hendrickson JE
J Clin Apher; 2024 Jun; 39(3):e22127. PubMed ID: 38803152
[TBL] [Abstract][Full Text] [Related]
3. Successful "on-demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors.
Corbingi A; Metafuni E; Di Salvatore M; Putzulu R; Chiusolo P; Schinzari G; Massini G; Rossi E; Zini G; Cassano A; Sica S; Piccirillo N
J Clin Apher; 2022 Feb; 37(1):65-69. PubMed ID: 34822725
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
Malinowska I; Romiszewski M; Smalisz K; Stelmaszczyk-Emmel A; Nasilowska-Adamska B; Krol M; Urbanowska E; Brozyna A; Baginska-Dembowska B
Transfus Apher Sci; 2021 Jun; 60(3):103077. PubMed ID: 33583716
[TBL] [Abstract][Full Text] [Related]
5. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
Zhuang L; Boriboonnangkul P; Wang S; Yuan S
Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
[TBL] [Abstract][Full Text] [Related]
7. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
8. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients.
Antelo ML; Altuna A; Gimeno JJ; Ferreiro JJ; Amunárriz C; Mateos JJ; Zalba S; Alkorta A; Rifón J; Arroyo JL; Uresandi A; Moreno JA; Nájera MJ; Pinzón S; García A; Vallejo JC;
Transfus Apher Sci; 2021 Jun; 60(3):103130. PubMed ID: 33840626
[TBL] [Abstract][Full Text] [Related]
9. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
[TBL] [Abstract][Full Text] [Related]
10. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
[TBL] [Abstract][Full Text] [Related]
12. First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.
Bekadja MA; Mansour B; Ouldjeriouat H; Entasoltan B; Bouchama S; Charef L; Amani K; Hakiki N; Bouamama F; Osmani S; Brahimi M; Arabi A; Bouhass R; Yafour N
Transfus Apher Sci; 2021 Jun; 60(3):103070. PubMed ID: 33612450
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.
Prakash VS; Malik PS; Sahoo RK; Pramanik R; Choudhary P; Varshney AN; Kumar L
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):44-51. PubMed ID: 34452863
[TBL] [Abstract][Full Text] [Related]
14. A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
Bhunia N; Abu-Arja R; Stanek JR; Mehyar LS; Shaw PJ; Kang HJ; Stein J; O'Brien TA; Roberts CH; Lee AC; Loeb DM; Ozkaynak MF; Dalal JD; Strahlendorf C; Goyal RK; Shenoy SS; Rangarajan HG
Transfusion; 2021 Mar; 61(3):894-902. PubMed ID: 33475172
[TBL] [Abstract][Full Text] [Related]
15. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
Zhuang L; Lauro D; Wang S; Yuan S
J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
17. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
[TBL] [Abstract][Full Text] [Related]
18. Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma.
Taenaka R; Takigawa K; Okamura K; Obara T; Nishimura N; Kohno K; Aoki K; Ogawa R
Transfus Apher Sci; 2021 Dec; 60(6):103279. PubMed ID: 34563457
[TBL] [Abstract][Full Text] [Related]
19. Impact of Plerixafor Use at Different Peripheral Blood CD34
Shah EE; Young RP; Wong SW; Damon LE; Wolf JL; Shah ND; Leavitt AD; Loeffler P; Martin TG
Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
Ri M; Matsue K; Sunami K; Shimazaki C; Hayashi A; Sunaga Y; Sasaki T; Suzuki K
Int J Hematol; 2017 Oct; 106(4):562-572. PubMed ID: 28527129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]